Mesoblast’s $90 Million Refinancing and Expansion of Senior Debt Facility

Latham & Watkins represented Mesoblast in the transaction.Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has successfully…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Laura Testa

Author: Laura Testa

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here